CN108310304A - The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law - Google Patents
The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law Download PDFInfo
- Publication number
- CN108310304A CN108310304A CN201810346874.0A CN201810346874A CN108310304A CN 108310304 A CN108310304 A CN 108310304A CN 201810346874 A CN201810346874 A CN 201810346874A CN 108310304 A CN108310304 A CN 108310304A
- Authority
- CN
- China
- Prior art keywords
- parts
- prescription
- inducing diuresis
- extraction
- law
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Rule the prescription preparation method for treating chronic nephritis by law the purpose of the present invention is to provide a kind of inducing diuresis with bland drug, contain 10 parts of almond, 10 parts of roud cardamon seed in terms of mass fraction in per portion prescription, each 30 parts of 30 parts of, Bi Collettiis of coix seed, 12 parts of Herba Lycopi, 15 parts of motherwort, 20 parts of Gorgon fruit, 20 parts of talcum, 20 parts of Poria cocos；The above raw material is mixed, is pulverized and sieved, coarse powder is obtained；Coarse powder is put into supercritical extraction reactor, compression pump is opened and is pressurized to 25MPa, extraction temperature is 60 DEG C, and extraction time is 5 hours, cycling extraction 23 times extract liquor；To extract liquor decompression, revolving, dry inducing diuresis with bland drug method prescription.The beneficial effects of the invention are as follows damp-heat type nephritis patient albuminuria can be reduced, kidney region fibrosis is reduced, to play therapeutic effect.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, are related to a kind of prescription preparation method of inducing diuresis with bland drug ruling by law treatment chronic nephritis.
Background technology
The concealment of chronic glomerulonephritis onset, protracted course, often merging albuminuria, blood urine and progressive renal function decline
It moves back, currently, generally believing that albuminuria and renal fibrosis, renal failure, immune factor etc. are closely related.The illness rate of the disease
Height, easily leads to the deterioration of renal function, finally causes renal failure (CRF), is the important protopathy of CRF.
Immune-mediated kidney damage plays important role during the progression of disease of chronic nephritis.Immune response
Induction inflammation cell is activated, and the inflammatory cell of activation can generate special inflammatory mediator, is damaged so as to cause glomerulus
Evil.There are many inflammatory cells to participate in chronic nephritis morbidity, they have a variety of effects, and can interact, influence each other, slowly
Property ephritis inflammatory reaction is present in the network of such a extremely complex inflammatory cell and medium interaction, and proinflammatory
Row cytokine TNF-α, IL-6 and IL-17 are the inflammatory cytokines wherein to play an important role, three be both immunological regulation because
Son, and it is important inflammatory mediator.TNF-α can not only be generated by macrophage, also can certainly be divided by mesangial cell (MC)
It secretes, and MC is promoted to secrete IL-6.And the IL-6 that MC largely secretes acts on MC in turn, stimulates its Proliferation, Differentiation, the two
Reciprocal causation forms a kind of vicious circle.IL-17 is secreted by Th17 cells, participates in many inflammatory reactions and autoimmunity
Property disease morbidity, IL-17 can interact with TGF- α, IL-1 β, generate synergistic effect, the common tune for participating in inflammatory reaction
Section.Therefore research TNF-α, the variation of IL-6 and IL-17 in vivo, contribute to immunopathogenesis and the guidance of inquiring into chronic nephritis
Clinical treatment.
Chronic nephritis belongs to motherland's medicine " oedema ", " consumptive disease " and " pain in the back " scope, and ancient Chinese medicine doctor is thought, the morbidity of this disease is more
For asthenia in origin and asthenia in superficiality,《Hospital examines》Middle discussion, " disease of lower coke, blame in damp and hot ", XUE Sheng-bai discussion " lunar internal injury, wet drink stop gathering,
It is objective evil again extremely, inside and outside coupling, therefore disease is damp and hot ", illustrate in chronic nephritis pathogenic process or sthenia symptoms caused by asthenia, or because of real cause assertive evidence
It usually mutually promotes between standard card, to cause vicious circle pathologically, thus the basic pathogenesis of this disease is retention of damp-heat in the interior,
Applicant's early-stage study using inducing diuresis with bland drug method (drug by almond, FRUCTUS AMOMI ROTUNDUS, coix seed, Bi Collettiis, Herba Lycopi, motherwort, Gorgon fruit,
Talcum, Poria cocos etc.) treatment chronic nephritis damp-heat type patient, it is found that this method can reduce the urine albumen amount of patient, improves patient's
Clinical symptoms integrate, and mitigate the kidney region fibrosis serological index of patient, to have in terms of efficient and clinical remission rate
There is apparent advantage.Based on the above Research foundation, the therapy mechanism of inducing diuresis with bland drug method is expanded on further, intends by clinical real
It tests, by taking orally inducing diuresis with bland drug drug to damp-heat type chronic nephritis patient, analyzes pretherapy and post-treatment patient's TNF-α, IL-6 and IL-17
Variation illustrate inducing diuresis with bland drug method to the therapy mechanism of damp-heat type chronic ephritis to the expression variation based on proinflammatory inflammation factor.
Invention content
Rule the prescription preparation method for treating chronic nephritis by law the purpose of the present invention is to provide a kind of inducing diuresis with bland drug, it is of the invention
Advantageous effect is can to reduce damp-heat type nephritis patient albuminuria, kidney region fibrosis is reduced, to play therapeutic effect.
The technical solution adopted in the present invention is to follow the steps below：
Step 1：Raw material selects；
Contain 10 parts of almond, 10 parts of roud cardamon seed, 30 parts of coix seed, Bi Collettii each 30 in terms of mass fraction in per portion prescription
Part, 12 parts of Herba Lycopi, 15 parts of motherwort, 20 parts of Gorgon fruit, 20 parts of talcum, 20 parts of Poria cocos；
Step 2：The above raw material is mixed, is pulverized and sieved, coarse powder is obtained；
Step 3：Coarse powder is put into supercritical extraction reactor, compression pump is opened and is pressurized to 25MPa, extraction temperature is 60 DEG C, extraction
It is 5 hours to take the time, and cycling extraction 2-3 time obtains extract liquor；
Step 4：To extract liquor decompression, revolving, dry inducing diuresis with bland drug method prescription.
Further, the prescription can reduce damp-heat type nephritis patient albuminuria, kidney region fibrosis be reduced, to damp-heat type
Chronic nephritis inflammatory factor has intervention effect.
Specific implementation mode
The present invention is described in detail With reference to embodiment.
Prescription effect experiment of the present invention is as follows：
ELISA kit：ELISA kit needed for this research is bought from Shenzhen Neobioscience companies.Plasma wrea
The indexs such as nitrogen, serum creatinine, twenty-four-hour urine protein quantification, blood uric acid, serum PTH：Heart assist is completed in the court's medical test.
Case source
In December, -2019 in January, 2018 is hospitalized in Jining Hospital of Chinese Medicine and the patients with chronic glomerulonephritis of treat-and-release, diagnosis accord with
Close the diagnostic criteria of doctor trained in Western medicine chronic nephritis and the syndrome diagnostic criterion of Chinese medicine kidney deficiency syndrome of dampness-heat.It is included in research object 60.
Diagnostic criteria
It is proposed with reference to nephrosis branch of China Association of Traditional Chinese Medicine in 2006《The diagnosis of chronic glomerulonephritis, differentiation of symptoms and signs for classification of syndrome
And efficacy evaluation (tentative program)》.
1. onset concealment, make slow progress, protracted inflammation, clinical manifestation can gently weigh or when it is light when weight.As the state of an illness is sent out
Exhibition, renal function are faded, and the later stage may occur in which situations such as anaemia, electrolyte disturbance, blood urea nitrogen, serum creatinine increase.
2. uroscopy is abnormal, often there are long duration albuminuria, quantity of proteinuria normal<3.5g/24h (difference is micro- for blood urine
The red blood cell of the common polymorphic change of mirror), can there are cylindruria, the performances such as different degrees of oedema, hypertension.
3. in the course of disease acute attack can be induced because of reasons such as respiratory tract infection, there is the performance of similar acute nephritis.
4. it is primary glomerulonephritis that it is diagnosable, which to exclude secondary glomerulonephritis rear,.
Syndrome Differentiation of Traditional Chinese Medicine standard：
It is promulgated with reference to national towel Drug Administration year《New Chinese medicine guideline of clinical investigations》.
Primary symptom：Skin curtain swells, covers disease, abscess of throat, dark urine, scorching hot or Pan pain unfavorable, appearance or limbs edema.
Minor symptom：Bitter or dry, mouth glues；Chamber is bored indigestion and loss of appetite, dry to be not intended to drink；Yellow and greasy fur, arteries and veins child number or sliding number.
Case inclusion criteria
1. meeting the chronic glomerulonephritis of the above diagnostic criteria, the dialectical patient for syndrome of dampness-heat.2. in January, 2018-
The patient for the chronic glomerulonephritis that in January, 2018 treats in The Hospital Attached to Jining Medical College.3. 18-65 one full year of life, men and women are unlimited.
Case exclusion criteria
1. not meeting above-mentioned diagnostic criteria and inclusion criteria.2. chronic nephropyelitis；3. the kidney damage secondary to general disease
Evil；4. renal insufficiency 4-5 phases patient or renal failure person；5. gestation and women breast-feeding their children；6. merge intentionally, brain, liver
With the severe primaries disease patient such as hemopoietic system.
Stop experiment case standard
1. serious adverse events, complication occurs；2. compliance is poor, it is unable to follow-up, data is not complete.
Experiment packet and therapeutic scheme
(1) 1. this group of control group is removed and is avoided using regular western medicine treatment to aggravate the reversible factors of renal damage, includes
The influence of food and drug, various infection, damage, Water-Electrolyte and acid-base imbalance etc..2. keeping on a diet, nutritional support, give
High-quality low albumen Di Pity diet, sufficient heat and vitamin etc..3. each systematic complication of anti symptom treatment, specific treatment is according to trouble
Depending on person's situation.Treatment time is 3 months.
(2) this group of experimental group is on the basis of regular western medicine treatment, and cooperation inducing diuresis with bland drug method (side) is treated, it is damp and hot very
Person adds honeysuckle, Cortex Phellodendri etc.；Deficiency of vital energy person adds Sijunzi Tang (ginseng, Rhizoma Atractylodis Macrocephalae, Poria cocos, Radix Glycyrrhizae)；The deficiency of yang adds Morinda officinalis, rhizoma cibotii etc.；
Deficiency of Yin person adds erzhi pills (fruit of glossy privet, eclipta)；Blood stasis notably adds Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis etc.：Add rhizoma imperatae, madder etc. with blood urine person.
It is decocted in water for oral dose, daily 1 dose, 20min takes after meal in three times.According to the principle of sample emergency, symptomatic treatment in acute condition, it is slow then
Zhi Qiben, Urine proteins give Yishen Jianpi Chinese medicine with righting gas, the course for the treatment of 3 months after turning out cloudy.Observation and Testing index
(1) ordinary circumstance
Name, gender, age, the course of disease, underlying etiology etc.；
(2) lab index
Detect blood urea nitrogen, serum creatinine, twenty-four-hour urine protein quantification, blood uric acid, serum PTH.
(3) ELISA detects TNF-α, IL-6 and IL-17 contents
Blood was collected respectively before patient's treatment and after treatment, and Aspirate supernatant carries out inflammatory factor content after centrifugation
ELISA is detected, and according to data creating standard curve and equation, conversion obtains the content of each sample cell factor.Statistical analysis
Statistical procedures are carried out using 19.0 softwares of SPSS, data are indicated using mean ± standard deviation (x ± s), poor between group
It is different to use one-way analysis of variance (One-wayANOVA), P<0.05 has statistical significance for difference.
By the present invention in that being treated to clinical syndrome of dampness-heat patients with chronic glomerulonephritis with inducing diuresis with bland drug method, clinical treatment is evaluated
The change of ELISA method detection serum proinflammatory row cytokine TNF-α, IL-6 and IL-17 is respectively adopted in effect, patient before and after treatment
Change, to inquire into the mechanism that syndrome of dampness-heat chronic nephritis is treated in inducing diuresis with bland drug ruling by law based on inflammatory regulation mechanism.
Inducing diuresis with bland drug method is to rule the method treated the prescription of chronic nephritis and treated by law by inducing diuresis with bland drug, according to clinical verification
Really it is effectively directed to the common method for the treatment of of chronic nephritis, this method can reduce damp-heat type nephritis patient albuminuria, reduce between kidney
Matter fibrosis, to play therapeutic effect.It is also highly effective to the treatment of chronic nephritis syndrome of dampness-heat.It is scorching to damp-heat type chronic ephritis
Inflammation factor has intervention effect.
The above is only the better embodiment to the present invention, not makees limit in any form to the present invention
System, every any simple modification that embodiment of above is made according to the technical essence of the invention, equivalent variations and modification,
Belong in the range of technical solution of the present invention.
Claims (2)
1. the prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law, it is characterised in that follow the steps below：
Step 1：Raw material selects；
Contain 10 parts of almond, 10 parts of roud cardamon seed in terms of mass fraction, each 30 parts of 30 parts of coix seed, Bi Collettii, pool in per portion prescription
It is 12 parts blue, 15 parts of motherwort, 20 parts of Gorgon fruit, 20 parts of talcum, 20 parts of Poria cocos；
Step 2：The above raw material is mixed, is pulverized and sieved, coarse powder is obtained；
Step 3：Coarse powder is put into supercritical extraction reactor, compression pump is opened and is pressurized to 25MPa, extraction temperature is 60 DEG C, when extraction
Between be 5 hours, cycling extraction 2-3 time obtains extract liquor；
Step 4：To extract liquor decompression, revolving, dry inducing diuresis with bland drug method prescription.
2. treating the prescription preparation method of chronic nephritis according to a kind of inducing diuresis with bland drug ruling by law described in claim 1, it is characterised in that：Institute
Damp-heat type nephritis patient albuminuria can be reduced by stating prescription, kidney region fibrosis be reduced, to damp-heat type chronic ephritis inflammatory factor
With intervention effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810346874.0A CN108310304A (en) | 2018-04-18 | 2018-04-18 | The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810346874.0A CN108310304A (en) | 2018-04-18 | 2018-04-18 | The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310304A true CN108310304A (en) | 2018-07-24 |
Family
ID=62897128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810346874.0A Pending CN108310304A (en) | 2018-04-18 | 2018-04-18 | The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310304A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108339083A (en) * | 2018-05-21 | 2018-07-31 | 济宁医学院附属医院 | The prescription of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
-
2018
- 2018-04-18 CN CN201810346874.0A patent/CN108310304A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108339083A (en) * | 2018-05-21 | 2018-07-31 | 济宁医学院附属医院 | The prescription of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103638136B (en) | Cordyceps QISHEN CAPSULE | |
| CN113318201A (en) | Health food for reducing uric acid and preparation method thereof | |
| CN102631595B (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN109045229A (en) | The Chinese medicine composition and preparation method thereof for treating urarthritis | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN108310304A (en) | The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law | |
| CN108339083A (en) | The prescription of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law | |
| CN110064016B (en) | Traditional Chinese medicine composition for regulating immune state of chronic kidney disease and preparation method thereof | |
| Goto et al. | Clinical evaluation of the effect of daio (rhei rhizoma) on the progression of diabetic nephropathy with overt proteinuria | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN102552702A (en) | Application of Dendrobium officinale in preparing medicaments for treating low gastric acidity type chronic atrophic gastritis | |
| CN103948754A (en) | Drug for treating renal-deficiency humid-heat type chronic nephritis | |
| CN101224241B (en) | Melanin regeneration pill | |
| CN101732652A (en) | Chinese patent medicament for treating ulcerative colitis | |
| CN105168881B (en) | It is a kind of to treat chronic renal failure I, the Chinese medicine composition of II phase | |
| CN106880828A (en) | A kind of Chinese medicine composition for treating spleen kidney qi deficiency of yang type primary nephrotic syndrome | |
| CN101439147A (en) | Haiqihuang granules as well as preparation method thereof and pharmacy use | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN114917310B (en) | Traditional Chinese medicine for treating 3-5 stages of chronic kidney disease and preparation method thereof | |
| CN103656299A (en) | Chinese herbal preparation for treating chronic glomerulonephritis | |
| CN116115724B (en) | Traditional Chinese medicine composition, pharmaceutical preparation, preparation method and application thereof | |
| CN110123977B (en) | Traditional Chinese medicine composition for treating diabetes combined with gout by external application | |
| CN115137785B (en) | Membranous kidney prescription for treating idiopathic membranous nephropathy | |
| CN116036162B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof | |
| CN116920047B (en) | Novel traditional Chinese medicine compound composition for treating myocardial injury related to coronavirus infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180724 |